HIV Vaccine Studies
In the United States, HIV disproportionately infects certain groups and populations; however, HIV can infect anyone. Worldwide there are currently over 40 million people infected with HIV. That number is growing.
Developing a vaccine is our best hope to control HIV/AIDS. The Vanderbilt HIV Vaccine Study needs healthy, uninfected adults (ages 18-55) from all walks of life to help find a vaccine to prevent HIV infection.
There is no risk of HIV infection from the study vaccines. Volunteers must be available locally for approximately 18 months. Volunteers will be compensated.
Call 936-7327 or email vic.sorrell@vumc.org for more information.
You can help fight the HIV/AIDS epidemic.
In order to develop a vaccine that will work for everyone, we need help from everyone! ALL RACIAL AND ETHNIC GROUPS ARE ENCOURAGED TO CONTACT OUR PROGRAM.
Current Studies
HVTN 300 Part B: A first-in-human Phase 1 clinical trial to evaluate the safety and immunogenicity of stabilized CH505 TF chTrimer in healthy, HIV-uninfected adult participants
HVTN 144: A Phase 1/2 clinical trial evaluating the safety and immunogenicity of an HIV-1 vaccine regimen using adenovirus vectors. The study assesses the vaccine's ability to induce strong antibody and T-cell responses for broad protection against multiple HIV-1 subtypes.
HVTN 300: A Phase 1 clinical trial evaluating the safety and immunogenicity of an HIV-1 vaccine regimen with mosaic antigens designed to elicit broad immune responses. The trial assesses the vaccine's ability to generate protective antibodies and T-cell responses against diverse HIV-1 strains.
HVTN 304: A Phase 1 clinical trial evaluating the safety and immunogenicity of a novel HIV-1 vaccine regimen based on trimeric envelope glycoproteins. The trial assesses the vaccine's ability to induce neutralizing antibodies and strong T-cell responses for broad protection against HIV-1 infection.
HVTN 307: A Phase 1 clinical trial evaluating the safety and immunogenicity of a novel HIV-1 vaccine regimen using lipid nanoparticle-encapsulated mRNA technology. The study aims to assess the vaccine's ability to elicit broad and potent antibody and T-cell responses to prevent HIV-1 infection across diverse viral strains.
Upcoming Studies
HVTN 309: A phase 1 clinical trial in adult participants without HIV and in overall good health to evaluate the safety and immunogenicity of CD4BS CH505M5 Pr-NP1 followed by CH505 TF chTrimer boost both adjuvanted with either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
HVTN 318: A Phase 1 open-label, non-randomized clinical trial to evaluate the safety and immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in adult participants who previously participated in the HVTN706/MOSAICO study and remain without HIV. (Projected start September 2025)
HVTN 319: A Phase 1 clinical trial designed to evaluate the safety, tolerability, and immunogenicity of an HIV-1 vaccine regimen based on mosaic and trimeric antigens. The trial aims to determine the vaccine's ability to elicit broad, cross-clade antibody and T-cell responses to protect against diverse HIV-1 strains.
HVTN 321: A first-in-human (FIH) Phase 1 open-label clinical trial evaluating a prime-boost regimen of immunogens designed to induce multiple specificities of HIV-1 envelope (Env) V3-glyca-specific broadly neutralizing antibodies (V3G bnAbs). Both vaccine components consist of modified mRNA encapsulated in lipid nanoparticles (LNPs) that, when translated in cells, produce HIV-1 Env gp150 transmembrane trimers and will be administered in a dose-escalation approach.